SCN5A compound heterozygosity mutation in Brugada syndrome: Functional consequences and the implication for pharmacological treatment.

Joviano-Santos JV, Santos-Miranda A, Neri EA, Fonseca-Alaniz MH, Krieger JE, Pereira AC, Roman-Campos D

Open source

DOI
10.1016/j.lfs.2021.119646
Published
2021 Aug 1
Container
Life sciences
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.lfs.2021.119646,
  title = {SCN5A compound heterozygosity mutation in Brugada syndrome: Functional consequences and the implication for pharmacological treatment.},
  author = {Joviano-Santos JV and Santos-Miranda A and Neri EA and Fonseca-Alaniz MH and Krieger JE and Pereira AC and Roman-Campos D},
  year = {2021},
  journal = {Life sciences},
  doi = {10.1016/j.lfs.2021.119646},
  url = {https://doi.org/10.1016/j.lfs.2021.119646}
}

RIS

TY  - JOUR
TI  - SCN5A compound heterozygosity mutation in Brugada syndrome: Functional consequences and the implication for pharmacological treatment.
AU  - Joviano-Santos JV
AU  - Santos-Miranda A
AU  - Neri EA
AU  - Fonseca-Alaniz MH
AU  - Krieger JE
AU  - Pereira AC
AU  - Roman-Campos D
PY  - 2021
JO  - Life sciences
DO  - 10.1016/j.lfs.2021.119646
UR  - https://doi.org/10.1016/j.lfs.2021.119646
ER  - 

APA

JV, J., A, S., EA, N., MH, F., JE, K., AC, P., & D, R. (2021). SCN5A compound heterozygosity mutation in Brugada syndrome: Functional consequences and the implication for pharmacological treatment.. Life sciences. https://doi.org/10.1016/j.lfs.2021.119646

Source records